IntramuscularActive immunisation against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenza type BChild: ≥2 months to <3 years As primary immunisation: 3 doses of 0.5 mL each to be given at 2, 3 and 4 months via deep inj into the anterolateral muscles of the thigh or the deltoid muscles of the upper arm. Alternatively, 2 doses of 0.5 mL each to be given at least 2-month intervals. As booster immunisation: 0.5 mL at least 6 months after last dose but, before 18 (if 3 doses primary immunisation) or between 11-13 months of age (if 2 doses). Refer to literature as dosage may vary with brand and local guidelines.
|
Hypersensitivity. Moderate or severe acute febrile illness or acute infection. History of encephalopathy within 1 week of pertussis vaccine.
|
Patient with family or personal history of convulsions, sudden infant death syndrome (SIDS); Guillain-Barre syndrome, mild acute illness, ≥40.5°C temperature, hypotonic-hyporesponsive episode or crying for ≥3 hours within 48 hours or seizures within 3 days of pertussis vaccine; progressive neurological disorder, immunosuppression, bleeding disorder (e.g. thrombocytopenia).
|
Significant: Fever (≥38°C temperature), hypotonic-hyporesponsive episode, inconsolable crying, irritability, seizures, syncope, Guillain-Barre syndrome, brachial neuritis; apnoea (premature infants).
Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
General disorders and administration site conditions: Fatigue, inj site reactions (e.g. tenderness, pain, oedema, erythema).
Metabolism and nutrition disorders: Appetite loss.
Nervous system disorders: Somnolence.
Psychiatric disorders: Restlessness.
Potentially Fatal: Hypersensitivity or anaphylaxis reactions.
|
Monitor for signs and symptoms of hypersensitivity for 30 minutes, syncope for 15 minutes, apnoea in premature infants for 2-3 days after vaccination.
|
Decrease effect with immunosuppressive agents (e.g. corticosteroids, antimetabolites). Increased febrile reactions with pneumococcal conjugate or measles-mumps-rubella-varicella (MMRV) vaccine.
|
May interfere with urine antigen detection for Haemophilus influenzae type B infection for a week.
|
Description:
Mechanism of Action: DTP-HIB-HBV-POL vaccine, a combination of diphtheria and tetanus toxoids, acellular pertussis, Haemophilus influenzae type B conjugate, recombinant hepatitis B and inactivated poliovirus vaccines, promotes immunity against diphtheria, tetanus, pertussis, Haemophilus influenzae type B or hepatitis B infection and poliomyelitis.
|
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
|
|
|
J07CA09 - diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B ; Belongs to the class of combined bacterial and viral vaccines.
|
Anon. Diphtheria and Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), Poliovirus (Inactivated) and Haemophilus influenzae B Conjugate (Adsorbed) Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 19/07/2018. Buckingham R (ed). Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, and Haemophilus Influenzae Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/07/2018. Joint Formulary Committee. Diphtheria with Tetanus, Pertussis, Hepatitis B, Poliomyelitis and Haemophilus Influenzae Type B Vaccine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/07/2018.
|
Đăng xuất
